跳至主要内容
临床试验/CTRI/2024/07/071061
CTRI/2024/07/071061尚未招募Unknown

Post-approval, observational study to assess clinical safety and effectiveness of Azelnidipine and Telmisartan in management of Diabetic HTN - TELAZ

Torrent Pharmaceuticals Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
Unknown
状态
尚未招募
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • 1.Male or Female patients 18 to 65 years.
  • 2.Known cases of T2DM with HTN as Treatment naïve or uncontrolled receiving background ARB therapy for at least four weeks
  • 3.Patients with systemic Blood pressure =140/90 mm/Hg.

排除标准

  • 1.Patients with T1DM.
  • 2.Patients with impaired hepatic function with liver enzymes 5X ULN
  • 3.Current state as pregnant or breast-feeding
  • 4.Patients not willing for follow –up during the course of the study @ 8W and 24W

研究者

发起方
Torrent Pharmaceuticals Ltd.

相似试验